Skip to main content

Table 4 Percentage positive antibody responses of the four representative DENV peptides of broadly immunogenic E protein epitopes to human sera of four DENV serotypes

From: Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins

Serotype of the sera P4/E (72–88) P5/E (89–104) P14/E (394–410) P15/E (418–434) P17/E (458–474)
  DENV1
SRCPTQGEATLVEEQDA
DENV1
NFVCRRTFVDRGWGNG
DENV1
KGSSIGKMFEATARGAR
DENV1
TWADFGSIGGVFTSVGK
DENV1
IGILLTWLGLNSRSTSL
DENV1 12 (100%) 12 (100%) 10 (83%) 12 (100%) 10 (83%)
DENV2 12 (100%) 12 (100%) 10 (83%) 12 (100%) 9 (75%)
DENV3 12 (100%) 12 (100%) 12 (100%) 12 (100%) 9 (75%)
DENV4 12 (100%) 12 (100%) 12 (100%) 12 (100%) 9 (75%)
  DENV2
RCPTQGEPSLNEEQDKRF
DENV2
KRFVCKHSMVDRGWGNGCGL
DENV2
KKGSSIGQMIETTMRGAK
DENV2
AILGDTAWDFGSLGGVF
DENV2
IITWIGMNSRSTSLSVSL
DENV1 12 (100%) 12 (100%) 10 (83%) 0 (0%) 12 (100%)
DENV2 12 (100%) 12 (100%) 10 (83%) 0 (0%) 12 (100%)
DENV3 12 (100%) 12 (100%) 10 (83%) 0 (0%) 12 (100%)
DENV4 12 (100%) 12 (100%) 10 (83%) 0 (0%) 12 (100%)
  DENV3
SRCPTQGEAILPEEQDQNH
DENV3
CKHTYVDRGWGNGCGLF
DENV3
KKGSSIGKMFEATARGAR
DENV3
WDFGSVGGVLNSLGKMVH
DENV3
IGIGVLLTWIGLNSK
DENV1 12 (100%) 0 (0%) 12 (100%) 6 (50%) 0 (0%)
DENV2 12 (100%) 0 (0%) 12 (100%) 9 (75%) 0 (0%)
DENV3 12 (100%) 0 (0%) 12 (100%) 10 (83%) 0 (0%)
DENV4 12 (100%) 0 (0%) 12 (100%) 6 (50%) 3(25%)
  DENV4
TRCPTQGEPYLKEEQDQQY
DENV4
CRRDVVDRGWGNGCGLF
DENV4
SIGKMFESTYRGAKRMAI
DENV4
WDFGSVGGLFTSLGKAVH
DENV4
LVLWIGTNSRNTSMAM
DENV1 2 (17%) 9 (75%) 0 (0%) 10 (83%) 0 (0%)
DENV2 10 (83%) 9 (75%) 0 (0%) 12 (100%) 0 (0%)
DENV3 2 (17%) 10 (83%) 0 (0%) 9 (75%) 1 (8%)
DENV4 12 (100%) 6 (50%) 0 (0%) 9 (75%) 0 (0%)
Serotype of the sera P2/E (30–46) P3/E (60–76) P13/E (377–393) P16/E (424–440)
  DENV1
CVTTMAKDKPTLDIELL
DENV1
CIEAKISNTTTDSRCPT
DENV1
YIVVGAGEKALKQCWFK
DENV1
SIGGVFTSVGKLVHQVF
DENV1 12 (100%) 10 (83%) 0 (0%) 0 (0%)
DENV2 9 (75%) 0 (0%) 12 (100%) 12 (100%)
DENV3 6 (50%) 9 (100%) 9 (75%) 10 (83%)
DENV4 0 (0%) 12 (100%) 9 (75%) 10 (83%)
  DENV2
SCVTTMAKNKPTLDFELI
DENV2
EIKITPQSSITEAFLTGY
DENV2
FGDSYIIIGVEPGQLKL
DENV2
WDFGSLGGVFTSIGKALH
DENV1 3 (25%) 10 (83%) 1 (8%) 0(0%)
DENV2 12 (100%) 12 (100%) 6 (50%) 0 (0%)
DENV3 6 (50%) 12 (100%) 0 (0%) 0 (0%)
DENV4 0 (0%) 9 (75%) 6 (50%) 0 (0%)
  DENV3
GCVTTMAKNKPTLDIEL
DENV3
LCIEGKITNVTTDSR7
DENV3
KALKINWYKKGSSIGKMF
DENV3
VLNSLGKMVHQIFGSAY
DENV1 0 (0%) 0 (0%) 1 (8%) 0 (0%)
DENV2 0 (0%) 0 (0%) 5 (42%) 2 (17%)
DENV3 4 (33%) 0 (0%) 12 (100%) 0 (0%)
DENV4 5 (42%) 0 (0%) 0 (0%) 3 (25%)
  DENV4
GCVTTMAQGKPTLDFEL
DENV4
SISNITTATRCPTQQGEPY
DENV4
FDSYIVIGVGNSALTLH
DENV4
WDFGSVGGLFTSLGKAVH
DENV1 2 (17%) 9 (75%) 0 (0%) 0 (0%)
DENV2 10 (83%) 3 (25%) 1 (8%) 0 (0%)
DENV3 3 (25%) 10 (83%) 0 (0%) 0 (0%)
DENV4 6 (50%) 12 (100%) 0 (0%) 0 (0%)
  1. Number of sera samples giving positive responses out of twelve sera samples tested per serotype (DENV1, DENV2, DENV3, DENV4), and its percentage (%) are shown. The peptide sequences from each serotype for a respective epitope are shown. The corresponding epitope/peptide sequences from cross serotypes are based on the peptide arrays; DENV1 (Singapore/S275/1990 (NR-4551)), DENV2 (New Guinea C (NR-507)), DENV3 (Sleman/1978 (NR-511)), DENV4 (Dominica/814669/1981 (NR-512))